Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2022-08-02 00:00:00 ET · period of report 2022-08-02 · accession 0001737287-22-000057 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-02 | 2022-08-02 | ALLO | Amado Rafael | CMO, EVP of R, D | S - Sale | $11.97 | -2,000 | 540.3K | -0.4% | -$23.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-02 | S | D | 2,000 | $11.97 | 540,257 | D | — | — | (F1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in February 2022. |